{
  "E138A": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138A,G140A,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138A,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138A,G140S,Q148H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "E138A,G140S,Y143H,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138A,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138A,S147G,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "E138K": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138K,G140A,Q148K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140A,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "E138K,G140A,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "E138K,G140C,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140S,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138K,G140S,Q148R,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,G140S,S147G,Q148R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138K,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138K,Q148R,N155H,G163K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138K,S147G,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E138K,Y143C,N155H,G163R,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "E138K,Y143R,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E138T": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
  },
  "E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "E157Q,G163R": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "E157Q,R263K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN263K": "R263K is selected in vitro by EVG, DTG, and BIC, and in patients receiving DTG. It reduces DTG and BIC susceptibility about 2-fold and EVG susceptibility somewhat more. "
  },
  "E92G": {
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility but does not reduce susceptibility to RAL, DTG, or BIC."
  },
  "E92G,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility but does not reduce susceptibility to RAL, DTG, or BIC."
  },
  "E92G,T97A,N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN92G": "E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility but does not reduce susceptibility to RAL, DTG, or BIC.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q": {
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,E138K,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,E138K,Y143C,N155H,S230R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,G140S,Q148R,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92Q,Q95K,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility."
  },
  "E92Q,T97A": {
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,Y143H,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,T97A,Y143R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "E92Q,Y143H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "E92V,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN92V": "E92V is a rare non-polymorphic mutation selected in vitro by an investigational INSTI. It causes intermediate and high-level reductions in EVG and RAL susceptibility, respectively."
  },
  "F121Y": {
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It causes intermediate to high-level reductions in RAL and EVG susceptibility but does not appear to reduce DTG or BIC susceptibility."
  },
  "F121Y,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It causes intermediate to high-level reductions in RAL and EVG susceptibility but does not appear to reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "G140A,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "G140A,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "G140A,Q148R,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140A,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility."
  },
  "G140S,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "G140S,Q148H,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "G140S,Q148H,E157Q,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148H,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "G140S,Q148H,N155H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "G140S,Q148H,V151A": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN151A": "V151A is an extremely rare non-polymorphic mutation associated with minimally reduced susceptibility to RAL and EVG."
  },
  "G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "G140S,Q148K,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148N": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148N": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility. Q148N is a rare INSTI-selected mutation that causes ~3-fold reduced EVG susceptibility and may represent a reversion from Q148H or Q148K."
  },
  "G140S,Q148N,G163R": {
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148N": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility. Q148N is a rare INSTI-selected mutation that causes ~3-fold reduced EVG susceptibility and may represent a reversion from Q148H or Q148K.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "G140S,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "G140S,Q148R,G163K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R,G163R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Q148R,N155H,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "G140S,Q148R,R263K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN263K": "R263K is selected in vitro by EVG, DTG, and BIC, and in patients receiving DTG. It reduces DTG and BIC susceptibility about 2-fold and EVG susceptibility somewhat more. "
  },
  "G140S,Y143H,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "G140S,Y143H,Q148H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G140S,Y143R,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "G163K": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "H51Y": {
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility."
  },
  "H51Y,E92Q,G140S,Q148K,N155H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "H51Y,E92Q,G140S,Q148K,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "H51Y,G140S,Q148K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility."
  },
  "H51Y,T66A,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN51Y": "H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG susceptibility (~2 to 3-fold). It does not reduce RAL or DTG susceptibility.",
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderate reduction in EVG susceptibility but does not appear to reduce RAL, DTG, or BIC susceptibility."
  },
  "L74M,E138K,G140C,Q148R,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,E138T,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,E92Q,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "L74M,G140A,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,G140C,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,G140C,Q148R,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,G140S,Q148H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,G140S,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,G140S,Q148R,E157Q": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,Q95K,T97A,Y143C,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,Q95K,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,Q95K,Y143C,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility."
  },
  "L74M,T97A,E138A,Y143C": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,E138K,Y143C,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,E138K,Y143R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143C,G163R,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143C,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143G": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143G,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143R,G163K": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,T97A,Y143S,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "L74M,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,Y143C,N155H,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "L74M,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "N155H,E157Q": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "N155H,E157Q,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,E157Q,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "N155H,R263K": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN263K": "R263K is selected in vitro by EVG, DTG, and BIC, and in patients receiving DTG. It reduces DTG and BIC susceptibility about 2-fold and EVG susceptibility somewhat more. "
  },
  "N155H,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "N155T": {
    "IN155ST": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility. N155S/T are extremely rare non-polymorphic mutations selected in vitro by investigational INSTIs. They reduce RAL and EVG susceptibility somewhat less than does N155H."
  },
  "P145S": {
    "IN145S": "P145S is a rare non-polymorphic mutation selected in vitro by EVG and rarely in patients receiving EVG. It causes high-level resistance to EVG but not to RAL or DTG."
  },
  "Q146P": {
    "IN146P": "Q146P is a rare non-polymorphic mutation selected in vitro by EVG which causes low-to-intermediate reductions in EVG susceptibility."
  },
  "Q148H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "Q148R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "Q148R,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "Q148R,N155H": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "Q95K": {
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,E138K,S147G,Q148R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility."
  },
  "Q95K,T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "Q95K,T97A,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "Q95K,Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN95K": "Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility."
  },
  "R263K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN263K": "R263K is selected in vitro by EVG, DTG, and BIC, and in patients receiving DTG. It reduces DTG and BIC susceptibility about 2-fold and EVG susceptibility somewhat more. "
  },
  "S147G": {
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility."
  },
  "S147G,Q148R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility."
  },
  "S153F": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN153YF": "S153Y/F are rare non-polymorphic mutations selected in vitro by EVG, DTG, and BIC. S153Y/F reduce RAL, DTG, and possibly BIC susceptibility about 2-fold and EVG susceptibility about 4-fold."
  },
  "S230R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "T66A": {
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderate reduction in EVG susceptibility but does not appear to reduce RAL, DTG, or BIC susceptibility."
  },
  "T66A,E92Q": {
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderate reduction in EVG susceptibility but does not appear to reduce RAL, DTG, or BIC susceptibility.",
    "IN92Q": "E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility."
  },
  "T66A,G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN66A": "T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderate reduction in EVG susceptibility but does not appear to reduce RAL, DTG, or BIC susceptibility."
  },
  "T66I": {
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG, RAL, and DTG. It reduces EVG susceptibility about 10-fold but does not reduce RAL, DTG, or BIC susceptibility."
  },
  "T66I,T97A,G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG, RAL, and DTG. It reduces EVG susceptibility about 10-fold but does not reduce RAL, DTG, or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T66I,T97A,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG, RAL, and DTG. It reduces EVG susceptibility about 10-fold but does not reduce RAL, DTG, or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T66I,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN66I": "T66I is a non-polymorphic mutation selected in patients receiving EVG, RAL, and DTG. It reduces EVG susceptibility about 10-fold but does not reduce RAL, DTG, or BIC susceptibility."
  },
  "T66K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN66K": "T66K is a non-polymorphic mutation selected in patients receiving EVG. It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and low-level DTG resistance. Its effect on BIC is not known."
  },
  "T66K,L74M,G140S,Q148R,E157Q": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN66K": "T66K is a non-polymorphic mutation selected in patients receiving EVG. It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and low-level DTG resistance. Its effect on BIC is not known.",
    "IN74MIF": "L74M/I are polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 10% of patients and L74I occurs in 3% to 20% of patients depending on subtype. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, they contribute reduced susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
  },
  "T97A": {
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138A,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138A,Y143K": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K,E157Q": {
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K,Q148R,N155H,G163K": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E138K,S147G,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN138KAT": "E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",
    "IN147G": "S147G is a non-polymorphic mutation selected primarily in patients receiving EVG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E157Q": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,E157Q,G163R": {
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,F121Y": {
    "IN121Y": "F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It causes intermediate to high-level reductions in RAL and EVG susceptibility but does not appear to reduce DTG or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G140S,Q148H": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G140S,Q148R,N155H,G163R": {
    "DTGHigh": "There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN140SAC": "G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.",
    "IN148HKR": "Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. Q148H/R/K are associated with high-level reductions in RAL and EVG susceptibility particularly when they occur In combination with E138 or G140 mutations. Alone, Q148H/K/R have minimal effects on DTG and BIC susceptibility. But in combination with E138 and G140 mutations they cause moderate and occasionally high-level reductions in DTG and BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G163K": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,G163R": {
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,N155H": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,N155H,G163K": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,N155H,G163R": {
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C,G163R,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143C,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143G": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143H,N155H,E157Q": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143H,N155H,G163R": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R,G163K": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143S": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "T97A,Y143S,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility.",
    "IN97A": "T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to EVG, RAL, DTG, and possibly BIC."
  },
  "V151A": {
    "IN151A": "V151A is an extremely rare non-polymorphic mutation associated with minimally reduced susceptibility to RAL and EVG."
  },
  "V151L": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN151L": "V151L is an extremely rare non-polymorphic mutation that confers intermediate / high-level reduced susceptibility to RAL and EVG and low-level reduced susceptibility to DTG."
  },
  "Y143C": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility."
  },
  "Y143C,E157Q,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "Y143C,G163K,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "Y143C,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "Y143C,G163R,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "Y143C,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "Y143C,N155H,E157Q,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "Y143C,N155H,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "Y143C,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "Y143H": {
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides)."
  },
  "Y143H,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143H": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility. Y143H is a less-common mutation at this position that is likely a transitional mutation between the wildtype Y amino acid and the mutant R (which differs from the wildtype Y by two nucleotides).",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "Y143K": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility."
  },
  "Y143R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility."
  },
  "Y143R,E157Q": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN157Q": "E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
  },
  "Y143R,G163R": {
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility."
  },
  "Y143R,N155H": {
    "DTGLow": "There is evidence for low-level DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143CR": "Y143C/R are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate to high-level reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce DTG or BIC susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
  },
  "Y143S": {
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility."
  },
  "Y143S,N155H,G163K,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN155H": "N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",
    "IN163RK": "G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  },
  "Y143S,S230R": {
    "DTGIntermediate": "There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.",
    "IN143KGSA": "Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",
    "IN230R": "S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It causes low-level reductions in DTG susceptibility."
  }
}